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have remained very poor, and do not clearly vary according 
to classiication, phase of study or use of diferent thera-
peutic interventions. Future studies should harmonize out-
come and prognostic variable reporting to enable accurate 
meta-analysis and better exploration of prognosis.
Keywords Pediatrics · Brain stem glioma · DIPG · 
Prognostic · Survival and systematic review
Abbreviations
DIPG  Difuse intrinsic pontine glioma
BSG  Brain stem glioma
RCT  Randomised-controlled trial
CNS  Central nervous system
WHO  World Health Organisation
MRI  Magnetic resonance imaging
CENTRAL  The Cochrane Central Register of Controlled 
Trials
OS  Overall survival
USA  United States of America
UK  United Kingdom
Introduction
Brain stem gliomas (BSG) account for approximately 
10–20% of all childhood CNS tumors. An estimated 
350–400 pediatric cases (3–4 per 100,000 pediatric popula-
tion) were diagnosed yearly in the United States of Amer-
ica (USA) from 2007 to 2011 [1] and 40 cases per year in 
the United Kingdom (UK) (approximately 3 per 100,000 
pediatric population) from 1996 to 2005 [2]. Brainstem gli-
omas are not categorized according WHO classiication of 
CNS tumors as with gliomas in other locations, rather they 
are grouped according to location and appearance using 
Abstract Diagnosis of a pediatric high grade brain stem 
glioma is devastating with dismal outcomes. This system-
atic review and meta-analysis was undertaken to determine 
the survival rates and assess potential prognostic factors 
including selected interventions. Studies included involved 
pediatric participants with high grade brain stem glio-
mas diagnosed by magnetic resonance imaging or biopsy 
reporting overall survival rates. Meta-analysis was under-
taken using a binomial random efects model. Sixty-ive 
studies (2336 participants) were included. Meta-analysis 
showed 1  year overall survival (OS) of 41% (95% coni-
dence interval (CI) 38–44%, I-sq 52%, 2083 participants), 
2 year OS of 15.3% (95% conidence interval 12–20%, I-sq 
73.1%, 1329 participants) and 3  year OS of 7.3% (95% 
conidence interval 5.2–10%, I-sq 26%, 584 participants). 
Meta-analyses of median overall survival results was not 
possible due to the lack of reported measures of variance. 
Subgroup analysis comparing date of study, classiication 
of tumor, use of temozolomide, non-standard interventions 
or phase 1/2 versus other studies demonstrated no difer-
ence in survival outcomes. There was insuicient data to 
undertake subgroup meta-analysis of patient age, duration 
of symptoms, K27M histone mutations and AVCR1 muta-
tions. Survival outcomes of high grade brain stem gliomas 
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magnetic resonance (MRI) T1 and T2 weighted imaging 
[3, 4], although recently, there has been discussion of the 
need for histological diagnosis by biopsy and classiication 
according to location [5]. They are classiied broadly into 
two groups: low grade (or focal/exophytic) BSGs and dif-
fuse intrinsic pontine gliomas (DIPG) including those con-
irmed histologically or those diagnosed using radiology 
alone. Difuse tumors are typically iniltrating astrocyto-
mas, which can be grade 2–4 depending on histopathologi-
cal features and have a poorer outcomes when compared to 
focal BSGs [6–8]. These types of BSGs usually arise from 
the pons but can occur in other locations. When they arise 
from the pons they are called DIPGs and typically repre-
sent 80% of patients with BSG. Fractionated external beam 
radiotherapy daily for 6 weeks is standard therapy for pedi-
atric high grade BSGs and chemotherapy with temozolo-
mide is frequently ofered. A Cochrane systematic review 
and meta-analyses by Hart et al. demonstrated a statistically 
signiicant increase in survival with the use of temozolmide 
in studies of adults with high grade gliomas (mortality 
hazard ratio 0.6, 95% CI 0.46–0.79). Although no previ-
ous meta-analyses have been completed on pediatric stud-
ies involving treatment with chemotherapy, the addition of 
chemotherapy does not clearly appear to improve survival 
in brain stem gliomas [9].
It has been hypothesized that certain features may be 
prognostic [6]. This includes duration of symptoms prior 
to diagnosis [7], age less than 3  years at diagnosis [10], 
histone H3 mutations [11], and ACVR1 mutations. Stud-
ies looking into the use of chemotherapy, immunotherapy, 
alternate radiotherapy including phase 1, 2 and 3 trials have 
not been able to demonstrate any signiicant improvement 
in outcome [9]. This is the irst systematic review to esti-
mate survival outcomes and assess proposed prognostic 
factors in pediatric high grade BSGs.
Methods
This systematic review followed a prespeciied proto-
col which was registered on PROSPERO [12] an interna-
tional database of health and social care systematic reviews 
(PROSPERO 2013:CRD42013006592).
Inclusion criteria
Designs of studies eligible included randomized-controlled 
trials (RCTs), quasi-RCTs and observational studies such 
as case-control, cohort studies including phase 1 and 2 tri-
als. Only studies of pediatric participants diagnosed with 
high grade BSGs from 1980 onwards by MRI or histology 
were included. Those including mixed participant groups 
(for example adult and pediatric patients) were included if 
pediatric outcomes were reported separately. Studies had 
to report one of the following survival outcomes: one, two, 
three, ive and/or greater than 5 year survival and median 
survival. To reduce the potential problems of publication 
bias introduced by very small studies, individual studies 
had to include a minimum of ten participants.
Identiication of trials
Database searches included MEDLINE, EMBASE, SCO-
PUS, The Cochrane Central Register of Controlled Tri-
als (CENTRAL) and trial registers from the year 1980 
onwards. The initial search was performed in February 
2015 and updated in September 2015 and January 2017. 
Other searches included reference lists of identiied and 
key review articles, abstracts from major conferences, hand 
searches of journals that comprised the most frequent ven-
ues for publications in this area and grey literature searches 
for unpublished data were also included. Searches were 
performed without language restrictions and attempts were 
made to obtain a translated copy if indicated.
Study selection
Study selection and data extraction was conducted in two 
stages:
• Two reviewers independently assessed the title and 
abstract for the studies using the inclusion and exclu-
sion criteria (H.H, A.P, A.F, S.R and S.H). Discrepan-
cies of studies potentially included in the review were 
addressed and those unresolved were referred to an 
independent assessor (R.P).
• Data was extracted by a researcher using a standardized 
form (H.H) and 50% was independently checked by a 
second person (A.P, S.H). When further information 
was required, the author of the paper was contacted.
 The study selection process and data extraction was piloted 
by applying the search strategy to a sample of 100 papers in 
order to check that the correct papers would be identiied, 
interpreted and analyzed. The pilot study was used to reine 
the inclusion criteria to ensure that it could be applied con-
sistently and that the correct data was extracted. The proto-
col published on the PROSPERO website was amended to 
include the modiied inclusion criteria.
Quality assessment
The Newcastle-Ottawa scale was adapted to assess the 
quality of studies as summarized in Table 1.
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Data synthesis
Meta-analysis of the subgroups high grade BSGs survival 
outcomes was performed using a random-efects model of 
logit-transformation proportions as proposed by Simmonds 
et al. [13].
We planned to assess if outcomes varied by speciic sub-
groups (DIPG vs. high grade BSGs, age less than 3 years 
and greater than 3  years, duration of symptoms less than 
6 months and above 6 months, K27 M H3.3 mutations and 
wild type H3.3 in DIPGs and AVCR1 mutations vs. non 
AVCR1 mutations). Where direct analyses had been per-
formed in contributing studies, we planned to compare the 
groups by performing a meta-analysis of pooled hazard 
ratios using a random-efects model. Where alternative data 
was provided, we intended to transform results into esti-
mates of hazard ratios using a previously describe schema 
[14].
For all results a p value of <0.008 were classed as sta-
tistically signiicant (according to Bonferroni correction 
for multiple outcomes) and calculated using the non-paired 
t-test. Heterogeneity was explored through consideration 
of study populations, study quality, predictor variables, 
and assessed in statistical terms using the I-squared (I-sq) 
statistic.
Results
Study selection
We identiied 1016 records through all electronic strate-
gies mentioned and a further 143 potentials from reference 
searching. Six hundred duplicated records were removed 
leaving 551 papers for title, key word and abstract screen-
ing (Fig.  1). Following relevance screening a total of 
100 papers were initially identiied for full review. Forty 
four papers satisied the inclusion criteria and a further 
21 papers were identiied by a comprehensive review of 
the references of included papers. This resulted in a total 
of 65 papers satisfying the eligibility criteria (see Fig. 1). 
The majority of studies were identiied from the initial and 
updated searches (n = 64). Only two studies were identiied 
through weekly electronic search updates [16, 17]. Included 
studies consisted of prospective cohorts (n = 42), retrospec-
tive cohorts (n = 23), case-controlled studies (n = 8) or 
randomized controlled trials (n = 3). Controls used in the 
case-controlled series included participants identiied from 
a review article, matched cohorts, historical controls, par-
ticipants included in a pilot study, and participants with 
non-brain stem diagnoses (for example ‘untreated regular 
and anaplastic astrocytoma’). The studies included in the 
systematic review represented 65 unique data sets (sum-
mary enclosed in supplementary ile 1 See Supplemen-
tary Material). Thirty ive papers were excluded following 
full text review for the following indications: duplicated 
data (n = 9), unable to separate data for relevant subgroup 
required (n = 4), majority of participants diagnosed via 
CT (n = 3), lack of primary data (n = 2), diagnosis prior to 
1980 (n = 3), fewer than ten relevant participants (n = 4), 
participants had recurrent or previously treated brain stem 
gliomas (n = 5), no reported survival data (n = 4), unable to 
translate paper (written in Polish, n = 1).
Quality of included studies
There is no currently accepted tool to evaluate the quality 
of prognostic studies, and the decision was made to use 
the Newcastle–Ottawa Scale [15]. This has three domains: 
selection, comparability and outcome. In this setting, 
“selection” refers to the representativeness of the patients 
within the study of the population to which it is drawn; 
“comparability” assesses any diferences between groups 
beyond the identiied potentially prognostic feature, and 
“outcome” refers to how complete and unbiased the assess-
ment of outcomes is in the study. A summary of the quality 
of studies is included in the supplementary ile 2 (See Sup-
plementary Material).
Selection quality
37.9% of included studies documented where the informa-
tion was taken from. All studies (100%) were awarded a 
point for the representativeness of exposed cohort.
Table 1  Modiied Newcastle-Ottawa Scale (adapted from [15])
Domain Outcome assessed
Selection Representativeness of the exposed cohort (one point)
Were BSG patients representative of the BSG patient that is 
typical in neurooncology practice?
Ascertainment of exposure (one point)
Did the study specify where the information conirming diag-
nosis was taken from?
Comparability Study controls for any additional factor (one point)
Outcome Was follow-up long enough for outcomes to occur (one point)
Did follow up occur for at least 1 year?
Adequacy of follow up of cohorts (one point)
Did the study account for all participants when assessing 
outcome of interest?
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Comparability quality
30.3% of included studies adjusted for additional factors. 
This included grade, prognostic factors, intervention and 
diagnostic measures.
Outcome assessment quality
The majority of studies reported the duration and adequacy 
of follow up (92.44 and 71.2% respectively).
Pooled estimates of survival
Overall survival could be estimated for 1, 2, and 3  year 
duration of follow-up. Appropriate 1 year overall survival 
was supplied in 63 data sets (2083 participants, Fig. 2) and 
estimated at 41% (95% conidence interval 38–44%, I-sq 
52%).
Meta-analysis of 2 year overall survival was 15.3% (95% 
conidence interval 12–20%, I-sq 71.3%) based on 40 data 
sets (1329 participants).
Meta-analysis of 3  year overall survival demonstrated 
only 7.3% surviving (95% conidence interval 5.2–10%, 
I-sq 25.6%) from 15 data sets (584 participants).
Only four data sets reported 5 year overall survival, and 
we therefore did not perform a meta-analyses. There was 
signiicant heterogeneity of the variance measures reported 
with median overall survival results and the majority of 
studies reported the range of data analysed. Due to the lack 
of reported variance measures of median overall survival, 
we were unable to complete a meta-analysis of median 
overall survival results.
Subgroup analyses
Subgroup analysis is summarized in Table  2. We were 
unable to demonstrate any statistically signiicant 
results for temozolomide (Fig.  3), dose of radiotherapy, 
Fig. 1  Summary of the screen-
ing process
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study-type, quality of study, mid-point date of study, clas-
siication of BSG as described in the studies i.e. DIPG 
versus other descriptions (including difuse pontine gli-
oma, difuse brain stem gliomas, difuse intrinsic brain 
stem gliomas, intrinsic pontine gliomas, intrinsic brain 
stem gliomas and high grade brain stem gliomas). Due 
to the lack of consistent data reporting in studies, we 
were unable to perform meta-analyses according to age 
Fig. 2  Pooled estimate of over-
all survival at 1 year
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of patients, duration of symptoms prior to presentation, 
speciic clinical features or K27M and AVCR1 histone 
mutations.
Publication bias
Publication bias for 1  year OS was assessed using the 
Sterne and Egger method and displayed in a funnel plot 
(Fig. 3). This was visually inspected, and there is no clear 
evidence of publication bias.
Discussion
To our knowledge this is the irst comprehensive system-
atic review of the literature that has attempted to summa-
rize survival outcomes in those diagnosed with high grade 
BSGs. We performed a systematic search of 1151 cita-
tions, and included 66 papers (2279 participants) which 
conirmed very poor overall survival for these tumors. The 
pooled results should be interpreted cautiously: conidence 
intervals for the point estimates are wide and there is mod-
erate heterogeneity. There was insuicient data to perform 
pooled analyses on 5 year and greater than 5 year OS.
Gliomas are graded according to the histological WHO 
classiication of brain tumors [18], whereas BSGs are 
diagnosed according to an MRI classiication since the 
publication of the article by Barkovich et  al. [3] which 
was based on three clinical trials (87 participants). The 
use of diferent phrases across the studies to describe 
potentially similar brain stem gliomas was noted (for 
example ‘DIPG’, ‘difuse pontine glioma’ and ‘intrinsic 
pontine glioma’). Although attempts to refer to the diag-
nostic criteria for inclusion in studies were reviewed to 
attempt to re-describe subgroup tumors consistently 
according to uniied criteria [3] it was not always clear 
whether diferent phrases were describing the same sub-
population of gliomas. Our analysis looking at studies 
clearly describing DIPG versus those using other phrases 
to refer to difuse/high-grade brain stem glioma suggest 
there is no clinically meaningful diference. However, 
the syntheses do demonstrate marked between-study 
Table 2  Overall survival at 
1 year and subgroup analysis
*Due to the lack of censoring information and IPD data all survival outcome percentages were calculated 
on the total number of participants included in the study rather than the number at each time point
Subgroup Number of 
participants*
1 year OS (%) 
(95% CI,
I-sq (%))
Diference (%), 
(95% CI,
p = value)
Classiication
 DIPGs 8018 40 (36–44% I-sq 48.5) 1.4 (−9.3 to 4.9%, 
p = 0.5) Other high grade BSGs 1065 42 (37–47% I-sq 55.6)
Drugs (DIPGs only)
 Temozolomide 202 42.7 (30–50%, 0) 1.2 (−6.2 to 17.1%, 
p = 0.3)  Non-Temozolomide 755 39 (34–44%, 54.1)
Phase of study (DIPGs only)
 Phase 1 & 2 studies 295 37.6 (32–43%, 0) 4.5 (−13.3 to 3%, 
p = 0.2) Non-phase 1 & 2 studies 723 42.1 (36–49%, 50.5)
Radiotherapy (DIPGs only)
 Conventional radiotherapy only 235 41.3 (32–52% 52.5) 1.6 (−13 to 12.3%, 
p = 0.1) Other interventions 783 39.7 (35–45% 47.6)
Midpoint study entry (DIPGs only)
 Before 2006 390 37.9 (30–47% 59.9) 1 (−10.1 to 11.2%, 
p = 0.9) From 2006 626 36.9 (31–43% 17.8)
Fig. 3  Funnel plot of total included studies reporting 1 year overall 
survival
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heterogeneity. This may be due to an intrinsic heterogene-
ity in the tumor population within classiication groups. 
For example, the histological grade of DIPGs varies from 
grade 2–4 and may have variable prognostic outcomes 
[19] although other authors did not demonstrate any clear 
diference in outcomes in analyses of histological grade 
[11, 20]. High grade BSGs may also include low grade 
features which have more favorable outcomes, for exam-
ple exophytic extensions which is deemed a low grade 
feature but may be present in gliomas classiied as high 
grade. The varying deinitions of difuse pontine gliomas, 
alongside the other classiications of BSGs and true bio-
logical variation in grading may contribute to the hetero-
geneity in meta-analysis, although between-study hetero-
geneity was not reduced when the alternative descriptions 
used by the authors were evaluated.
Subgroup meta-analyses of studies reported as DIPGs 
revealed similar 1–2 year OS outcomes, with no clear dif-
ferences seen over time, with the use of chemotherapy or 
diferent radiotherapy regimes. The lack of an observed 
diference should not be interpreted as evidence of a lack 
of efect of these interventions: the estimates are indirect, 
have wide conidence intervals and moderate unexplained 
heterogeneity.
Due to the lack of comparable prognostic data we were 
unable to perform meta-analyses of outcomes according 
to age, duration of symptoms, K27M histone and ACVR1 
mutations. We were also unable to perform pooled analyses 
of median overall survival due to the lack of variance meas-
ures reported.
Studies included in the analysis included prospective, 
retrospective, case-controlled cohort and non-blinded ran-
domized-controlled trials. The diferent study designs may 
contribute to the heterogeneity, unfortunately, we were 
unable to undertake a subgroup analysis due to the small 
number of particular study designs (only three randomized-
controlled studies were included).
We attempted to understand the source of the between-
study heterogeneity by subgroup analysis according to the 
overall score allocated using the Newcastle–Ottawa qual-
ity assessment tool; this did not indicate the quality of the 
study may have contributed to the heterogeneity. Attrition 
and reporting biases (including publication biases, selec-
tive outcome and selective analysis reporting) were also 
considered to see if they could contribute to heterogene-
ity reported. Visual inspection of the funnel plots of 1 year 
OS results using the Sterne and Egger method [21] (Fig. 3) 
did not show any clear evidence of publication bias. Miss-
ing data is a signiicant limiting factor in this review, both 
reducing precision, the possibility of speciic subgroup 
analyses, and remaining uncertainty about heterogene-
ity because of lack of clear information about the low of 
patients through each stage of the studies.
Applicability
Our review identiied serious inconsistencies in how the 
classiications of BSGs are reported. We found that they are 
deined using MRI, WHO grading or both making it dif-
icult to group results with conidence. A validated uniform 
diagnostic tool is required to limit the heterogeneity of 
results analysed. As MRI classiication appears to include 
gliomas of difering grades, performing biopsies on all 
diagnoses would improve accuracy and possibly, give bet-
ter indications of outcomes [22].
Systematic reviews have been hampered with inconsist-
ent outcome measures reporting in the past which resulted 
in the Core Outcome Measure in Efectiveness Trials 
(COMET) initiative. This aims to develop standardised 
outcomes known as ‘core outcome sets’ to reduce hetero-
geneity and diiculties in undertaking reviews. Inconsistent 
deinitions have also been previously reported in paediatric 
supportive care [23] which led to a study using the Delphi 
method to develop variables and outcomes to be used glob-
ally. While the COMET initiative is primarily concerned 
with interventional studies, a similar process to create a 
uniform core set of deinitions and outcome variables for 
paediatric brain stem gliomas would enable better analysis 
of studies and would reduce heterogeneity. Greater trans-
parency within studies is required with clear documentation 
of study methodology and protocol publication is required 
to minimise bias.
This systematic review is limited by the lack of adequate 
reporting of censored and missing participants. This could 
be overcome with mechanisms for sharing individual par-
ticipant data (IPD) in future studies. The value of IPD in 
interventional studies has been demonstrated in numer-
ous meta-analyses and its use has increased over the past 
decade.
The use of IPD in future systematic reviews would 
enable more consistent inclusion and exclusion criteria, 
account for missing data, verify published and use unpub-
lished results, would allow development of prognostic 
models and would reduce study heterogeneity. However, 
IPD analyses are labour intensive and time consuming. 
There are also concerns regarding the ethical implications 
of patient conidentiality, although this can be overcome by 
ensuring no patient identiiable data is accessible. A further 
problem that may be encountered is that study authors may 
not be contactable or willing to contribute which may result 
in biased meta-analyses. It is also important to remember 
that the quality of meta-analyses from IPD is dependent on 
the quality of studies included.
If studies do not supply IPD then clear information 
regarding censoring (how many and exact time), number 
at risk, clear documentation of measures of variance and 
when outcomes are assessed from should be supplied.
 J Neurooncol
1 3
Conclusion
Survival from high-grade brain stem gliomas in child-
hood remains very poor, with this systematic review esti-
mating that only four in ten young people diagnosed with 
a DIPG will be alive at one year after diagnosis. The stud-
ies assessed do not clearly demonstrate an improvement 
over time, or show any major impact of chemotherapy or 
alternative radiotherapy approaches. There were marked 
diferences between the studies which were not clearly 
explained as chance variation, diferences in the qual-
ity of the study report, the type of study (e.g. phase I/II), 
or the exact classiication of the tumors included. Com-
monly proposed prognostic features, such as age, duration 
of symptoms, and newer biological predictors, K27M 
histone and ACVR1 mutations, could not be assessed 
through insuicient reporting of this information.
Better understanding of how to predict outcomes from 
this rare group of pediatric brain tumors will require har-
monized and collaborative collection of data, pooled at 
an individual patient level, driven by a desire to develop 
new predictors and assess the validity of previously pro-
posed factors. As a coordinated global community, those 
involved in pediatric neuro-oncology are ideally placed 
meet this challenge.
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